GET MORE AI-GENERATED SIGNALS: December 02, 2024, 04:48 am ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

On Friday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $27.33 which represents a decrease of $-0.16 or -0.58% from the prior close of $27.49. The stock opened at $27.84 and ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...

Research analysts at HC Wainwright increased their FY2024 earnings estimates for shares of BridgeBio Pharma in a research ...

Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry giant. The next-generation, oral, ...

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...

European shares were higher today. The eurozone's STOXX 600 gained 0.16%, Germany's DAX gained 0.49% and France's CAC 40 rose ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO)的口服药物Attruby™ (acoramidis)获得美国食品和药物管理局 (FDA)批准，用于治疗成年ATTR-CM患者，旨在降低心血管死亡和住院率。这一批准是基于ATTRibute-CM第3期研究的积极结果。受此消息影响，BridgeBio股价上涨25%。